Cargando…
Drug discovery and development for neglected diseases: the DNDi model
New models of drug discovery have been developed to overcome the lack of modern and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceutical industry. With the pu...
Autores principales: | Chatelain, Eric, Ioset, Jean-Robert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084299/ https://www.ncbi.nlm.nih.gov/pubmed/21552487 http://dx.doi.org/10.2147/DDDT.S16381 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2019) -
Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma
por: Lim, Wilson, et al.
Publicado: (2018) -
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021) -
DNDI-6148: A Novel
Benzoxaborole Preclinical Candidate
for the Treatment of Visceral Leishmaniasis
por: Mowbray, Charles E., et al.
Publicado: (2021) -
Innovation in neglected tropical disease drug discovery and development
por: Weng, Hong-Bo, et al.
Publicado: (2018)